Use of bone densitometry to assess bone disease in aluminum toxicity complicating parenteral nutrition: A case report

Haifa Al Awadhi a, *, Ali Al Mehaidib a, Wajeeh Al Dekhail a, Hamdy Mulia b, Khalid Al Saleem a, Mohammed Abanemai a

a King Faisal Specialist Hospital & Research Center, Department of Pediatrics, Saudi Arabia
b King Faisal Specialist Hospital & Research Center, Department of Pharmacy, Saudi Arabia

Article info

Article history:
Received 15 October 2017
Accepted 1 January 2018
Available online 27 February 2018

Keywords:
Aluminum
Parenteral nutrition
Bone mineral density

Abstract

Aluminum toxicity affecting bone mineral density is a known complication of long-term parenteral nutrition. In this report, we describe a similar patient who suffered from bone disease and had a favorable response to chelation therapy using deferoxamine. We believe this may be a possible agent improving the life quality for the above mentioned group of patients.

1. Introduction

Patients on long-term Parenteral Nutrition (PN) are at risk of Aluminum (Al) toxicity, a condition that was first demonstrated in patients on hemodialysis (due to high Al concentration in dialysis fluids) [1]. Patients at risk of Al toxicity include preterm neonates, patients with compromised renal function, and any patient receiving long-term PN therapy.

One of the multiple complications of Al toxicity is bone disease. It can manifest in multiple forms including delayed longitudinal growth, osteopenia and rickets [2–4]. Bone immunohistochemical studies of these patients showed Al accumulation at the mineralization front [2–4].

As a protective measure, United States (US) Food and Drug Administration (FDA) set 5 mcg/kg/day as the upper limit of acceptable Al exposure. Furthermore, it mandates that products used in compounding PN should note the Al content on the label. Despite this, Poole et al. found that meeting these recommendations were not possible as patients exceeded the safe upper limits by 6–12 times [2,4,5].

In this report, we describe a patient who was on long term PN and developed Al toxicity. She had a favorable response to deferoxamine, i.e. reducing Al effects on bone. We assessed its efficacy, objectively, using bone mineral density.

2. Case

A 10 year-old- girl was diagnosed to have syndromic diarrhea in early childhood due to typical clinical features and hair electron microscopy. She was on cyclic PN since early infancy (10 years period).

Her PN was prepared at the hospital’s pharmacy as a customized PN solution which contained many PN components. She had a history of intermittent hospital admissions with central line infection requiring antibiotics treatment. At 9 years of age, the patient was admitted with gastroenteritis and dehydration and noted to have a high level of aluminum reaching 4.39 μmol/l (Table 1). The patient had no other Al related complications.

Thus our patient received 5 doses of deferoxamine, 300 mg IV (10 mg/kg), as a chelating agent. First 4 doses received on a weekly basis and the fifth dose was received 4 months later. Her bone densitometry one year prior to starting deferoxamine dose showed a lumbar spine Z-score of −4.2. The test was repeated 6 weeks post final dose of deferoxamine and showed a Z score of −3.2. At that time Al level decreased to 1.6 μmol/l. It further dropped to the upper limit of normal (0.4 μmol/l) seven months later. In addition to receiving the deferoxamine, PN contents were adjusted to minimize Al toxicity. Unfortunately we could not retrieve the exact
Table 1
Aluminum level and different trace-elements at different points of time, where 1: at time of highest Aluminum level encountered, 2: time of initial drop in Aluminum post treatment with deferoxamine, 3: time of Aluminum normalization, 4: last readings before patient travelling abroad. Normal ranges: Aluminum (0.00–0.40), Copper (12.6–25.1), Zinc (10.6–19.0), Pre-albumin (0.2–0.4), Albumin (32–48), Selenium (0.89–1.52), Iron (6.0–270), Iron saturation (9.08–0.43).

| Reading Number | Aluminum (umol/L) | Copper (umol/L) | Zinc (umol/L) | Pre-albumin (gm/L) | Albumin (gm/L) | Selenium (umol/L) | Iron (umol/L) | Iron Saturation |
|----------------|-------------------|----------------|--------------|--------------------|----------------|--------------------|---------------|----------------|
| 1              | 4.39              | 15.1           | 17.2         | 0.061              | 35             | 1.29               | 11.2          | 0.13           |
| 2              | 1.6               | 18.3           | 12.2         | –                  | 26             | 1.12               | –             | –              |
| 3              | 0.4               | 10.0           | 11.0         | –                  | 29             | 0.58               | –             | –              |
| 4              | 0.41              | 11.5           | 5.5          | –                  | 30             | 0.46               | –             | –              |

Fig. 1. Latest PN prescription of the patient prior to travelling. Note: RDA was kept as tolerated, in order to minimize hepato-toxicity associated with the long TPN course. It was not possible to maintain the goal due to the following limitations:

1) Aluminum toxicity related prolonged TPN course.
2) ON/off increase in LFTs.

Box 1: latest PN prescription of the patient prior to travelling. Note: RDA was kept as tolerated, in order to minimize hepato-toxicity associated with the long TPN course. It was not possible to maintain the goal due to the following limitations:

1) Aluminum toxicity related prolonged TPN course.
2) ON/off increase in LFTs.
changes done as the records have been discarded. Subsequently, the patient traveled abroad for social reasons and lost follow up in our hospital (Fig. 1).

3. Discussion

Infants and children are at greatest risk for Al toxicity from long term PN as they have high calcium requirements. In PN, Calcium gluconate has the highest Al contamination [1,6]. Another risk factor is that PN bypasses the gastrointestinal barrier and only 5% of the total Al in PN is ultra-filtratable by the kidneys. The rest is bound to plasma proteins [4,5]. On the other hand, studies have defined variable duration of PN that may increase risk of Al overload, varying from more than 10 days to more than 3 weeks [1,6]. Our patient was far beyond these cut limits.

Although bone biopsy is the only absolute proof of bone overload with Al, high plasma level of Al may indicate high risk of toxicity [1]. However, dual-energy x-ray absorptiometry (DXA) is one of the tests used to assess bone mineralization [3]. It assesses bone mineral density (BMD) using a 2 dimensional image (gm/cm²) [7]. A Z-score < −2 is considered low. Each – 1 drop in the Z-score is associated with almost 80% increase in risk of fracture [8]. Thus we used BMD to assess bone disease, objectively and directly, pre and post deferoxamine administration.

Deferoxamine has been used to treat Al toxicity in uremic patients and has resulted in increased bone formation [9]. Doses as low as 2.5 and 5 mg/kg/week, in patients on dialysis, were suggested [10,11]. However doses ranging from 10 to 100 mg/kg have been used as well. It increases Al removal during dialysis by forming a dialyzable low molecular weight aluminum-deferoxamine complex [10].

The American Academy of Pediatrics Committee on Nutrition and FDA recommended keeping a strict control of Al content in PN [4]. On the other hand, it is important to recognize that currently there is no method to ensure that PN contents are manufactured at the recommended lower Al concentrations [3,4]. To our knowledge, this is the first time response to deferoxamine was assessed, using bone densitometry, following chelation in patients on long term PN with Al toxicity. The improvement in the Z-score of this patient might support the routine use of bone densitometry for at risk patients. However, appropriately conducted interventional study may give stronger evidence.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

There is no conflict of interest to declare.

References

[1] Advenier E, Landry C, Colomb V, et al. Aluminum contamination of parenteral nutrition and aluminum loading in children on long term parenteral nutrition. J Pediatr Gastroenterol Nutr 2003;36:448–53.
[2] Popinska K, Kierkus J, Lyszkowska M, et al. Aluminum contamination of parenteral nutrition additives, amino acid solutions, and lipid emulsions. J Nutr 1999;15:683–6.
[3] Nehara D, Carlson S, Fallon E, et al. ASPEN clinical guidelines: nutrition support of neonatal patients at risk for metabolic bone disease. JPEN - J Parenter Enter Nutr 2013;37:570.
[4] Klein G, Leichtner A, Heyman M, et al. Aluminum in large and small volume parenteral nutrition: response to the food and drug administration notice of proposed rule by the North American society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1998;27:457–60.
[5] Poole R, Hintz S, Mackenzie N, et al. Aluminum exposure from pediatric parenteral nutrition: meeting the new FDA regulation. JPEN - J Parenter Enter Nutr 2008;32:242.
[6] Fawcett A, Edmond C, Isaac E, et al. Aluminum exposure from parenteral nutrition in preterm infants and later health outcomes during childhood and adolescence. Proc Nutr Soc 2011;70:299–304.
[7] Fung E, Vichinsky E, Kwiatskissi J, et al. Characterization of low bone mass in young patients with thalassemia by DXA, pQCT, and markers of bone turnover. Bone 2011;48:1305–12.
[8] Bachrach L, Sills I. Clinical report-bone densitometry in children and adolescents. Pediatrics 2011;127:189–94.
[9] Klein G. Aluminum in parenteral solutions revisited — again. Am J Clin Nutr 1995;61:449–56.
[10] Canteros A, Diaz-Corte C, Fernandez-Martin J, et al. Ultrafiltrable aluminum after very low doses of deferoxamine. Nephrol Dial Transplant 1998;13:1538–42.
[11] Kan W, Chein C, Wu C, et al. Comparison of low dose deferoxamine versus standard dose deferoxamine for treatment of aluminum overload among hemodialysis patients. Nephrol Dial Transplant 2010;25:1604–8.